Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Artivion, Inc.NYSE: AORT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $8M (cash outflow) rose 120.0% year over year, behind the +287.0% change in trailing-twelve-month capital expenditures. Sequentially, it fell 70.9% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.
Context
- Capital expenditures amounted to 8.8% of revenue in FY2025, up 6.0 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +120.0% toward the trailing-twelve-month pace of +287.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (39.04M) USD
- Year-over-year change
- -249.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.04M) | -249.0% |
| FY2024 | 2024-12-31 | (11.19M) | -50.6% |
| FY2023 | 2023-12-31 | (7.43M) | +30.7% |
| FY2022 | 2022-12-31 | (10.72M) | +18.1% |
| FY2021 | 2021-12-31 | (13.09M) | — |
Capital Expenditures vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 capital expenditures of $43.41M is the 4th largest of the 11 companies compared; the peer median is $14.48M.
- Its year-over-year change of +287.0% is the highest of 11, against a peer median of +30.7%.
- Capital expenditures amounts to 9.5% of revenue for AORT, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $217.71M | +15.7% | +0.8% | 7.4% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $217.08M | +16.4% | +11.9% | 3.4% |
| LTM Jul 2026 | $93.46M | +4.3% | +6.8% | 5.1% | |
| LTM Mar 2026 | $43.41M | +287.0% | +53.9% | 9.5% | |
| LTM Jun 2026 | $39.98M | +23.3% | +61.8% | 4.4% | |
| LTM Jun 2026 | $18.52M | +133.8% | +94.2% | 4.1% | |
| LTM Mar 2026 | $10.43M | +142.7% | +52.2% | 3.2% | |
| LTM Jun 2026 | $9.34M | +38.1% | -2.4% | 0.6% | |
| LTM Jun 2026 | $7.84M | -70.2% | -23.0% | 0.5% | |
| LTM Mar 2026 | $2.84M | +101.9% | — | 5.9% | |
| LTM Jun 2026 | $1.7M | +64.1% | -39.0% | — | |
| Peer median (excluding AORT) | $14.48M | +30.7% | +6.8% | 4.1% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Deferred Income Tax | (4.47M) | (1.72M) | (1.39M) | (1.51M) | 37K |
| Stock-Based Compensation | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Change in Working Capital | (33.23M) | (25.94M) | (16.19M) | (17.24M) | (22.16M) |
| Accounts Receivables | (11.56M) | (13.34M) | (4.05M) | (15.4M) | (7.27M) |
| Inventory | (18.38M) | (8.4M) | (14.36M) | (6.14M) | (15.28M) |
| Accounts Payables | (1.89M) | (1.96M) | 1.68M | 9.5M | 2.18M |
| Other Working Capital | (1.4M) | (2.23M) | 535K | (5.21M) | (1.8M) |
| Other Non-Cash Items | 15.26M | 6.91M | 29.6M | 15.9M | 3.64M |
| Operating Cash Flow | (2.59M) | (5.15M) | 18.83M | 22.24M | 38.13M |
| Capital Expenditures | (13.09M) | (10.72M) | (7.43M) | (11.19M) | (39.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 19M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (249K) | 0 | 6.93M | (17M) | (3M) |
| Investing Cash Flow | 5.66M | (10.72M) | (502K) | (28.19M) | (42.04M) |
| Debt Repayment | (3.09M) | (2.75M) | (2.77M) | (358K) | (2.46M) |
| Common Stock Issued | 0 | 0 | 0 | 5.73M | 13.07M |
| Common Stock Repurchased | (1.91M) | (1.8M) | (559K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.22M) | 2.91M | 4.2M | (3.17M) | 2.42M |
| Financing Cash Flow | (12.22M) | (1.64M) | 865K | 2.2M | 13.03M |
| Effect of Forex Changes | 2.2M | 1.85M | 401K | (1.73M) | 2.32M |
| Net Change in Cash | (6.95M) | (15.66M) | 19.59M | (5.48M) | 11.45M |
| Free Cash Flow | (15.68M) | (15.87M) | 11.4M | 11.05M | (911K) |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.